Repirinast is the Company's lead candidate for the treatment of CKD based on data showing it reduced fibrosis by 51% with statistical significance and showed an additive benefit to telmisartan in a ...
Intermittent hemodialysis was initiated with neurological improvement and a reduction in hypercalcemia. Abdominal CT scan revealed nephrocalcinosis, caliectasis, ureteral and testicular calcifications ...